TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Controlled Trial Comparing Hospital Inpatient vs Home Rehabilitation After Total Knee
Brief Summary: Total knee replacement (TKR) surgery is a common and highly effective treatment option for alleviating the pain and disability caused by chronic arthritis. The associated rehabilitation costs, however, impose a significant burden on the health system. In particular, inpatient rehabilitation - utilised by approximately 43% of private TKR recipients in NSW and 29% Australia-wide is of greatest concern, costing, on average, $7000 (AU) per inpatient episode.

The overarching aim of this study is to establish whether inpatient rehabilitation is necessary after TKR for patients with osteoarthritis (OA) who could otherwise be discharged directly home.

The main hypothesis to be tested by the proposed study is that TKR recipients who receive inpatient rehabilitation in addition to participating in a home programme, compared to patients who participate in a home programme only, will achieve a superior level of mobility. If superiority is shown, a cost-effectiveness analysis will be undertaken.

Secondary hypotheses to be tested relate to patient-reported knee pain and function, health-related quality of life, functional ambulation, and knee joint mobility.

Superiority in these outcomes will be evident at six months after surgery.


Options:
A: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Other: Very early supported discharge (VESD) | Arm Label: Control; Type: OTHER; Interventions: Other: Ordinary rehabilitation | Intervention Type: OTHER; Name: Very early supported discharge (VESD); Assigned to Arm(s): Active | Intervention Type: OTHER; Name: Ordinary rehabilitation; Assigned to Arm(s): Control
B: Arm Label: Home and hospital treatment groups; Type: N/A; Interventions: N/A
C: Arm Label: Hospital Inpatient Rehabilitation (HI); Type: ACTIVE_COMPARATOR; Interventions: Other: Hospital Inpatient Rehabilitation | Arm Label: Hybrid Home Programme (HO); Type: ACTIVE_COMPARATOR; Interventions: Other: Hybrid Home Programme (HO) | Intervention Type: OTHER; Name: Hospital Inpatient Rehabilitation; Assigned to Arm(s): Hospital Inpatient Rehabilitation (HI) | Intervention Type: OTHER; Name: Hybrid Home Programme (HO); Assigned to Arm(s): Hybrid Home Programme (HO)
D: Arm Label: Psychoeducative intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducative intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychoeducative intervention; Assigned to Arm(s): Psychoeducative intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of Growth of Infants Fed an Amino Acid Based Formula
Brief Summary: The primary objective of the clinical trial is to compare growth in infants (expressed as weight gain in g/day) consuming a new Amino Acid Formula to infants consuming a commercially available hypoallergenic formula over a period of 4 months.


Options:
A: Arm Label: Isoleucine; Type: ACTIVE_COMPARATOR; Interventions: Other: ORS + Isoleucine | Arm Label: ORS without Isoleucine; Type: PLACEBO_COMPARATOR; Interventions: Other: ORS without Isoleucine | Intervention Type: OTHER; Name: ORS + Isoleucine; Assigned to Arm(s): Isoleucine | Intervention Type: OTHER; Name: ORS without Isoleucine; Assigned to Arm(s): ORS without Isoleucine
B: Arm Label: Amino Acid Formula; Type: EXPERIMENTAL; Interventions: Other: Amino Acid Formula | Arm Label: Amino Acid commercial formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Amino Acid formula | Intervention Type: OTHER; Name: Amino Acid Formula; Assigned to Arm(s): Amino Acid Formula | Intervention Type: OTHER; Name: Amino Acid formula; Assigned to Arm(s): Amino Acid commercial formula
C: Arm Label: Experimental Infant Formula; Type: EXPERIMENTAL; Interventions: Other: Experimental Infant Formula | Intervention Type: OTHER; Name: Experimental Infant Formula; Assigned to Arm(s): Experimental Infant Formula
D: Arm Label: Control Study Formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Control Study Formula | Arm Label: Experimental Study Formula; Type: EXPERIMENTAL; Interventions: Other: Experimental Study Formula | Intervention Type: OTHER; Name: Control Study Formula; Assigned to Arm(s): Control Study Formula | Intervention Type: OTHER; Name: Experimental Study Formula; Assigned to Arm(s): Experimental Study Formula

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Newborn Vitamin A Supplementation in Improving Immune Function
Brief Summary: Vitamin A supplementation at birth may increase survival of infants through one year of age by reducing mortality from infectious diseases, though current studies are not conclusive on this point. The goal of our study is to determine if supplementation of newborn infants with 50,000 IU of vitamin A improves aspects of immune function that may be impaired by vitamin A deficiency. Our underlying assumption is that supplementation may thus decrease risk of death by improving immune function and the ability to survive infections. This project will be limited to the examination of the impact of vitamin A on immune function and will not aim to determine the impact on morbidity or mortality, which would require larger sample sizes. The hypotheses addressed by this study are as follows: Provision of vitamin A supplements to newborns at risk of vitamin A deficiency will (1) improve functioning of the thymus (the source of T lymphocytes, cells of the immune system that are important in response to infection and immunization); (2) enhance T lymphocyte-mediated responses to standard vaccines given at birth and early in infancy; and (3) improve gut barrier function (i.e., ability to prevent bacterial infection across the epithelial barrier), relative to provision of a placebo.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Vitamin A | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Vitamin A | Intervention Type: BIOLOGICAL; Name: Vitamin A; Assigned to Arm(s): 1, 2
B: Arm Label: Vitamin A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: retinyl palmitate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: retinyl palmitate; Assigned to Arm(s): Vitamin A | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Orange maize; Type: EXPERIMENTAL; Interventions: Other: Orange maize feeding | Arm Label: Blue vitamin A group; Type: ACTIVE_COMPARATOR; Interventions: Other: Vitamin A supplement | Arm Label: White; Type: PLACEBO_COMPARATOR; Interventions: Other: Oil only | Intervention Type: OTHER; Name: Orange maize feeding; Assigned to Arm(s): Orange maize | Intervention Type: OTHER; Name: Vitamin A supplement; Assigned to Arm(s): Blue vitamin A group | Intervention Type: OTHER; Name: Oil only; Assigned to Arm(s): White
D: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Newborn Vitamin A Supplementation in Improving Immune Function
Brief Summary: Vitamin A supplementation at birth may increase survival of infants through one year of age by reducing mortality from infectious diseases, though current studies are not conclusive on this point. The goal of our study is to determine if supplementation of newborn infants with 50,000 IU of vitamin A improves aspects of immune function that may be impaired by vitamin A deficiency. Our underlying assumption is that supplementation may thus decrease risk of death by improving immune function and the ability to survive infections. This project will be limited to the examination of the impact of vitamin A on immune function and will not aim to determine the impact on morbidity or mortality, which would require larger sample sizes. The hypotheses addressed by this study are as follows: Provision of vitamin A supplements to newborns at risk of vitamin A deficiency will (1) improve functioning of the thymus (the source of T lymphocytes, cells of the immune system that are important in response to infection and immunization); (2) enhance T lymphocyte-mediated responses to standard vaccines given at birth and early in infancy; and (3) improve gut barrier function (i.e., ability to prevent bacterial infection across the epithelial barrier), relative to provision of a placebo.


Options:
A: Arm Label: Vitamin A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: retinyl palmitate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: retinyl palmitate; Assigned to Arm(s): Vitamin A | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Vitamin A; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin A (retinyl palmitate). | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin A (retinyl palmitate). | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A (retinyl palmitate).; Assigned to Arm(s): Placebo, Vitamin A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU) | Arm Label: Vitamin A; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU) | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU); Assigned to Arm(s): Placebo, Vitamin A
D: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Newborn Vitamin A Supplementation in Improving Immune Function
Brief Summary: Vitamin A supplementation at birth may increase survival of infants through one year of age by reducing mortality from infectious diseases, though current studies are not conclusive on this point. The goal of our study is to determine if supplementation of newborn infants with 50,000 IU of vitamin A improves aspects of immune function that may be impaired by vitamin A deficiency. Our underlying assumption is that supplementation may thus decrease risk of death by improving immune function and the ability to survive infections. This project will be limited to the examination of the impact of vitamin A on immune function and will not aim to determine the impact on morbidity or mortality, which would require larger sample sizes. The hypotheses addressed by this study are as follows: Provision of vitamin A supplements to newborns at risk of vitamin A deficiency will (1) improve functioning of the thymus (the source of T lymphocytes, cells of the immune system that are important in response to infection and immunization); (2) enhance T lymphocyte-mediated responses to standard vaccines given at birth and early in infancy; and (3) improve gut barrier function (i.e., ability to prevent bacterial infection across the epithelial barrier), relative to provision of a placebo.


Options:
A: Arm Label: Vitamin A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: retinyl palmitate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: retinyl palmitate; Assigned to Arm(s): Vitamin A | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Peer-support for exclusive breastfeeding | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Peer-support for exclusive breastfeeding; Assigned to Arm(s): Intervention
D: Arm Label: Boys 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: OPV | Arm Label: Boys 2; Type: EXPERIMENTAL; Interventions: Biological: OPV plus BCG | Arm Label: Girls 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: OPV | Arm Label: Girls 2; Type: EXPERIMENTAL; Interventions: Biological: OPV plus BCG | Intervention Type: BIOLOGICAL; Name: OPV; Assigned to Arm(s): Boys 1 | Intervention Type: BIOLOGICAL; Name: OPV plus BCG; Assigned to Arm(s): Boys 2 | Intervention Type: BIOLOGICAL; Name: OPV; Assigned to Arm(s): Girls 1 | Intervention Type: BIOLOGICAL; Name: OPV plus BCG; Assigned to Arm(s): Girls 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Healthy Mothers on the Move (Healthy MOMs), was a prospective randomized controlled trial that aimed to demonstrate the effectiveness of a healthy lifestyle intervention to reduce risk factors for obesity and type 2 diabetes. This behavioral intervention was tailored to the needs of pregnant and postpartum Latino women. This study was conducted between 2004 and 2006 in southwest Detroit.


Options:
A: Arm Label: Nutritional counseling + exercise groups; Type: EXPERIMENTAL; Interventions: Behavioral: Nutritional counseling + exercise groups | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Nutritional counseling + exercise groups; Assigned to Arm(s): Nutritional counseling + exercise groups
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: MOMs Healthy Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy MOMs Healthy Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Healthy MOMs Healthy Lifestyle Intervention; Assigned to Arm(s): MOMs Healthy Lifestyle Intervention
C: Arm Label: Enhanced Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced standard care | Arm Label: Intensive lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive lifestyle intervention | Intervention Type: BEHAVIORAL; Name: Enhanced standard care; Assigned to Arm(s): Enhanced Standard Care | Intervention Type: BEHAVIORAL; Name: Intensive lifestyle intervention; Assigned to Arm(s): Intensive lifestyle intervention
D: Arm Label: Usual Care Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care Group | Arm Label: Lifestyle Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention Group | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention Group; Assigned to Arm(s): Lifestyle Intervention Group | Intervention Type: BEHAVIORAL; Name: Usual Care Group; Assigned to Arm(s): Usual Care Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Healthy Mothers on the Move (Healthy MOMs), was a prospective randomized controlled trial that aimed to demonstrate the effectiveness of a healthy lifestyle intervention to reduce risk factors for obesity and type 2 diabetes. This behavioral intervention was tailored to the needs of pregnant and postpartum Latino women. This study was conducted between 2004 and 2006 in southwest Detroit.


Options:
A: Arm Label: Lifestyle, follow-up, early care, standard care high/low risk; Type: OTHER; Interventions: Behavioral: Lifestyle: diet and exercise | Arm Label: Close follow-up; Type: OTHER; Interventions: Behavioral: Close follow-up: reporting diaries of food and exercise | Intervention Type: BEHAVIORAL; Name: Lifestyle: diet and exercise; Assigned to Arm(s): Lifestyle, follow-up, early care, standard care high/low risk | Intervention Type: BEHAVIORAL; Name: Close follow-up: reporting diaries of food and exercise; Assigned to Arm(s): Close follow-up
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: MOMs Healthy Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy MOMs Healthy Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Healthy MOMs Healthy Lifestyle Intervention; Assigned to Arm(s): MOMs Healthy Lifestyle Intervention
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Exercise, and Breastfeeding Intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Diet, Exercise, and Breastfeeding Intervention; Assigned to Arm(s): Intervention
D: Arm Label: Lifestyle Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Counseling | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle Counseling; Assigned to Arm(s): Lifestyle Counseling

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management
Brief Summary: The purpose of this study is to evaluate the short term efficacy and safety of tolvaptan in subjects hospitalized for worsening heart failure who have volume overload and one of the following: renal insufficiency, or hyponatremia or inadequate response to diuretic therapy. The primary variable for assessing efficacy will be self-assessed 7-point dyspnea score at 8 and 16 hours.


Options:
A: Arm Label: Tolvaptan; Type: EXPERIMENTAL; Interventions: Drug: Tolvaptan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tolvaptan; Assigned to Arm(s): Tolvaptan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Tolvaptan, Samsca; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tolvaptan or Samsca | Arm Label: sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo or sugar pill | Intervention Type: DRUG; Name: Tolvaptan or Samsca; Assigned to Arm(s): Tolvaptan, Samsca | Intervention Type: DRUG; Name: placebo or sugar pill; Assigned to Arm(s): sugar pill
C: Intervention Type: DRUG; Name: tolvaptan; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: satavaptan (SR121463B); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke
Brief Summary: This is a prospective, randomized, single blind, concurrent controlled, multi-center study. Patients presenting with symptoms of acute ischemic stroke who have evidence of a large vessel (2.5mm or greater in diameter) occlusion in the cerebral circulation will be assigned to either the Penumbra System with the Separator 3D or the Penumbra System without the Separator 3D. Each treated patient will be followed and assessed for 3 months after randomization. Up to 230 evaluable patients at up to 50 centers presenting with acute ischemic stroke in vessels accessible to the Penumbra Separator 3D System for revascularization within 8 hours of symptom onset. The hypothesis to be tested is that the safety and effectiveness of the Penumbra System with the Separator 3D for the revascularization of large vessel occlusion is not inferior to the Penumbra System alone.


Options:
A: Arm Label: Penumbra System with Separator 3D; Type: EXPERIMENTAL; Interventions: Device: Penumbra System with Separator 3D | Arm Label: Penumbra System alone; Type: ACTIVE_COMPARATOR; Interventions: Device: Penumbra System alone | Intervention Type: DEVICE; Name: Penumbra System with Separator 3D; Assigned to Arm(s): Penumbra System with Separator 3D | Intervention Type: DEVICE; Name: Penumbra System alone; Assigned to Arm(s): Penumbra System alone
B: Arm Label: IV t-PA with Solitaire™ revascularization device; Type: EXPERIMENTAL; Interventions: Device: Solitaire revascularization device | Arm Label: IV t-PA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous (IV) recombinant human tissue plasminogen activator (rtPA) | Intervention Type: DRUG; Name: Intravenous (IV) recombinant human tissue plasminogen activator (rtPA); Assigned to Arm(s): IV t-PA | Intervention Type: DEVICE; Name: Solitaire revascularization device; Assigned to Arm(s): IV t-PA with Solitaire™ revascularization device
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Endovascular thrombectomy/thrombolysis; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular thrombectomy/thrombolysis | Intervention Type: PROCEDURE; Name: Endovascular thrombectomy/thrombolysis; Assigned to Arm(s): Endovascular thrombectomy/thrombolysis
D: Arm Label: IA thrombolysis; Type: EXPERIMENTAL; Interventions: Other: Alteplase IA and/or mechanical thrombolysis | Arm Label: IV rtPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alteplase IV | Intervention Type: OTHER; Name: Alteplase IA and/or mechanical thrombolysis; Assigned to Arm(s): IA thrombolysis | Intervention Type: DRUG; Name: Alteplase IV; Assigned to Arm(s): IV rtPA

Answer: A